VERSAPEUTICS INC
San Diego, CA · Founded 2017 · CIK 0001731409 · Biotech · Private
Humanized monoclonal antibody (VersaMab-101) that blocks Wnt-Ryk receptor interaction to promote axonal regeneration in spinal cord injury
- Grants
- $7.0M
- 7 awards
- Sector median: 1
- Raised
- $3.8M
- 4 Form D · Jul 2020
- 75 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 3
- 0 granted · 3 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20172019202120232025
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $450,000 | |
| Private capital raised | Form D · SEC | $100,000 | |
| Private capital raised | Form D · SEC | $3,200,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Preclinical Development of VERSAMAB-101 for Spinal Cord Injury | $256,122 | |
| Federal grant | Department of Health and Human Services · Phase I · Pharmacokinetics and efficacy of intrathecal VersaMab-101 delivery foracute spinal cord injury | $495,137 | |
| Federal grant | Department of Health and Human Services · Phase I · Developing therapeutic antibodies for Alzheimer's disease | $498,534 | |
| Federal grant | Department of Health and Human Services · Phase I · Developing therapeutic antibodies for Alzheimer's disease | $489,628 | |
| Federal grant | Department of Health and Human Services · Phase II · Toxicology and Efficacy Studies of Intrathecal VersaMab-101 for spinal cord injury treatment | $2,380,552 | |
| Federal grant | Department of Health and Human Services · Phase II · Preclinical Toxicology Study of Intrathecal VersaMab-101 for spinal cord injury treatment | $1,430,030 | |
| Federal grant | Department of Health and Human Services · Phase II · Preclinical Toxicology Study of Intrathecal VersaMab-101 for spinal cord injury treatment | $1,455,927 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1849 | VITRISTOR LLC | — | — |
| 1850 | ASP Isotopes Inc. | — | $5.0M |
| 1851 | Kymera Therapeutics | — | — |
| 1852 | VERSAPEUTICS INC | — | $3.8M |
| 1853 | TBC I LLC | — | $1.0M |
| 1854 | InCarda Therapeutics, Inc. | — | $66M |
| 1855 | Recombinetics, Inc. | — | $45M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Jianhua CaiDirector
- Haipeng ChenDirector
- Haipeng ChengDirector
- Brian KwonDirector
- Connie ZhaoDirector
- Yimin ZouDirector · Executive Officer
Patents
- Antibody Variants Against Wnt Receptor Rykapplication
- Antibody Variants Against Wnt Receptor Rykapplication
- Antibody Variants Against Wnt Receptor Rykapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.